Velocity Clinical Research

Velocity Clinical Research Velocity is the world's leading integrated site organization.

Great research doesn’t happen by accident — it happens because great people are trained, supported, and set up to succee...
03/26/2026

Great research doesn’t happen by accident — it happens because great people are trained, supported, and set up to succeed.

Velocity’s PIVOT program is one of the clearest examples of that philosophy in action.

PIVOT was created to solve a simple but critical gap in clinical research: new P*s were often expected to “learn by osmosis,” depending on who happened to be working nearby. Now? Every new PI across our network enters a structured pathway that blends clinical guidance, operational discipline, and hands‑on mentorship.

And the results speak for themselves.
• Douglas Logan, MD — whose meticulous preparation and intellectual rigor became the gold standard
• Matthew Wenker, MD — who transformed the mentorship he received into the mentorship he now provides
• Daniel Williams, DO FAAEM DABOM — who leveraged PIVOT to transition from emergency medicine to high-quality research with confidence
• Abbie Youkilis, MD — who stepped into PI leadership smoothly, supported by the framework and expectations modeled for her

What PIVOT really does is create continuity.

The baton doesn’t get dropped. Standards don’t slip. Transitions don’t create gaps. And patients continue receiving consistent, high‑quality care across our entire footprint.

In a network as broad as Velocity’s, that consistency isn’t just an advantage — it’s a differentiator.

Learn how PIVOT strengthens the future of PI leadership: https://velocityclinical.com/mentorship-in-practice-how-pivot-strengthens-the-next-generation-of-principal-investigators/

What does it take to translate a career in policy and primary care into purpose-driven impact in clinical research?Abbie...
03/17/2026

What does it take to translate a career in policy and primary care into purpose-driven impact in clinical research?

Abbie Youkilis, MD, Principal Investigator at Velocity’s Cincinnati Springdale site, shares her unconventional path — from Capitol Hill to hospital medicine to leading trials that shape the future of chronic disease care.

In this new PI spotlight, Dr. Youkilis reflects on the experiences and values that guide her work:
✅ A systems-level understanding shaped by health policy and advocacy
✅ A deep commitment to patient care from decades in internal medicine
✅ A precision‑driven approach to trial oversight, documentation, and data integrity

From hyperlipidemia and diabetes studies to vaccine trials that improve access for underserved participants, she brings both clinical insight and human perspective to every protocol.

For physicians considering research, her advice is grounded and practical: shadow the work, talk to investigators, and understand the unique rhythm of trial delivery — a pace that creates space for science, preparation, and thoughtful care.

Read the full story here: https://velocityclinical.com/from-policy-to-practice-to-protocol-an-interview-with-dr-youkilis-on-making-the-move-to-clinical-research/

Velocity is continuing our series of high‑level industry conversations at this year’s World Vaccine Congress. We will ho...
03/13/2026

Velocity is continuing our series of high‑level industry conversations at this year’s World Vaccine Congress. We will host an exclusive “Dine and Discuss” session bringing together senior leaders from across the clinical research and vaccine ecosystem for an off‑the-record conversation with Richard H. Hughes IV.

With more than two decades of experience at the intersection of law, public health, and vaccine policy, Richard is a nationally recognized expert in vaccine regulation and policy strategy. He is a partner at Epstein Becker Green, a professorial lecturer in law at The George Washington University Law School, and formerly served as Vice President of Public Policy at Moderna during the rollout of the COVID‑19 vaccine. His thought leadership continues to help guide the industry’s understanding of today’s evolving vaccine landscape.

Through these intimate, candid discussions with leading voices across government, regulation, and life sciences, Velocity aims to provide sponsors and partners with direct access to the insights shaping the future of medical innovation.

Read more about this Dine and Discuss: https://velocityclinical.com/news

What does it take to advance cardiometabolic research with precision — and with humanity at the center?William Cromwell,...
03/06/2026

What does it take to advance cardiometabolic research with precision — and with humanity at the center?

William Cromwell, MD, FAHA, FNLA, Medical Director for Velocity’s Durham site and Lead of our Cardiometabolic CARE Council, brings more than 35 years of clinical practice, analytic development, and research leadership to this question.

In this new PI spotlight, Dr. Cromwell shares how his journey — from chemistry to clinical care to national research leadership — has shaped his philosophy on prevention, patient engagement, and scientific rigor.

He reflects on the principles that drive his work:
✅ Accurate, individualized assessment of cardiometabolic risk
✅ Precision therapies that target root causes, not just symptoms
✅ A network model that doesn’t just replicate sites — it scales success

From early lipid‑lowering therapies to today’s RNA-based and gene‑silencing innovations, his perspective honors both the science and the person sitting in front of him — imagining their own “good day” 10 years from now.

Read the full story here: https://velocityclinical.com/an-interview-with-care-council-lead-dr-cromwell-on-precision-prevention-and-scaling-success-in-cardiometabolic-research/

Velocity will be attending the World Vaccine Congress in Washington, D.C., March 30–April 2.Our team on the ground will ...
03/05/2026

Velocity will be attending the World Vaccine Congress in Washington, D.C., March 30–April 2.

Our team on the ground will include:
• Paul Evans, CEO
• Sarah Smiley, DO, FACP, Chief Physician Officer
• Andrew Reina, Chief Revenue Officer
• Jennifer Kochilaris, SVP, Strategy & Partnerships
• Dan Robitaille, VP, Business Development
• Chandler Starr, Senior Director, Business Development
• Uzair Zia, Executive Director, Operations
• Alyssa Precil, MPH, Director, Clinical Site Operations

As vaccine research continues to evolve at record pace, WVC is an important opportunity to connect with sponsors, CROs, and industry leaders on innovation, site performance, and advancing access to high‑quality clinical research.

If you’re planning to attend and would like to meet, we’d be happy to connect!

Velocity will be participating in SBPPC (Sociedade Brasileira de Profissionais em Pesquisa Clínica) in São Paulo, March ...
03/03/2026

Velocity will be participating in SBPPC (Sociedade Brasileira de Profissionais em Pesquisa Clínica) in São Paulo, March 19–21.

Renata Berardocco, EVP & Managing Director, Latin America, will be onsite connecting with sponsors, CROs, research professionals, and site leaders across Brazil’s rapidly growing clinical research landscape.

As Velocity expands its footprint in Latin America, SBPPC provides an important forum to discuss site performance, patient access, and the operational models needed to deliver high‑quality research across the region.

If you’ll be at SBPPC and would like to connect with Renata, feel free to reach out!

Next month, Nick Spittal, COO, will join a panel at the Medidata Solutions NEXT Conference focused on the innovations sh...
02/27/2026

Next month, Nick Spittal, COO, will join a panel at the Medidata Solutions NEXT Conference focused on the innovations shaping the next generation of clinical trials.

The discussion, Site Perspective Panel: Innovation for the Next Generation of Clinical Trials, will explore three key areas poised to streamline trials and reduce burden across stakeholders:
• AI & Intelligent Automation — Simplifying protocols and reducing system overload
• Protocol Optimization & Study Start-Up — Injecting site insights earlier to shorten activation timelines
• Patient-Centricity — Addressing recruitment and retention barriers to improve access

Panelists include:
• Christina Brennan, MD, SVP, Clinical Research, Northwell Health
• Irfan Khan, MD, CEO, Circuit Clinical
• Lisa Moneymaker, SVP & Chief Strategy Officer, Medidata

If you’re attending Medidata NEXT, join the session—and connect with Nick while you’re there.

How can sites diversify therapeutic areas without compromising quality?Next week, Evelyne Newton will share Velocity’s p...
02/26/2026

How can sites diversify therapeutic areas without compromising quality?

Next week, Evelyne Newton will share Velocity’s perspective on strategic therapeutic expansion SCRS Europe.

Through programmes like PIVOT, our experienced P*s train and mentor across the network, accelerating capability building while protecting quality. And when new sites join Velocity, they gain access to shared expertise and infrastructure that supports sustainable growth.

Diversification should strengthen your core not dilute it.

Read more: https://velocityclinical.com/diversifying-therapeutic-areas-from-opportunistic-growth-to-strategic-advantage/

Clinical research is changing—and the industry is demanding greater predictability, transparency, and data integrity tha...
01/30/2026

Clinical research is changing—and the industry is demanding greater predictability, transparency, and data integrity than ever before.

Andrew Reina, Chief Revenue Officer, shares why the traditional, relationship‑driven approaches to site selection are no longer enough—and how AI is reshaping feasibility into a more evidence‑driven, consistent, and confident process.

In his new article, Drew explores:
🔹 Why site selection needs a data reset as Sponsors push for trials that start faster and perform more predictably
🔹 How AI can transform feasibility from opinion-based to evidence-based decision-making
🔹 Why predictability is foundational to data quality—and how better alignment between protocol demands and site capabilities can reduce delays and downstream issues
🔹 How Velocity’s integrated network structure turns scale into intelligence, enabling meaningful performance analysis that many individual sites simply can’t support
🔹 How this new approach raises expectations across the network, driving continuous improvement and operational excellence

Velocity’s AI-powered feasibility and site intelligence tool launches its first phase this February—designed to bring more rigor, clarity, and confidence to site selection decisions.

This is more than a new technology. It’s a step toward a more predictable, data-led clinical research ecosystem—one that strengthens Sponsor relationships with transparent, evidence-backed insights.

Read the full article to see how AI can support your next study with greater confidence and consistency: https://velocityclinical.com/why-site-selection-needs-a-data-reset-and-how-ai-can-deliver-it/

We're gearing up for the SCOPE Summit, taking place February 2–5, 2026 in Orlando, FL. Our leadership team will be on si...
01/26/2026

We're gearing up for the SCOPE Summit, taking place February 2–5, 2026 in Orlando, FL. Our leadership team will be on site to connect, collaborate, and share insights on how Velocity is helping organizations move faster, smarter, and with greater impact.

Attending from Velocity:
• Paul Evans, President & CEO
• Nick Spittal, Chief Operations Officer
• Sarah Smiley, DO, FACP, Chief Physician Officer
• Andrew Reina, Chief Revenue Officer
• Jennifer Kochilaris, SVP, Strategic Partnerships
• Jennifer Carl, VP, Growth & Development
• Paul Kergides, VP, Business Development

If you’re attending SCOPE, we’d love to meet up and discuss the future of clinical research, strategic partnerships, and innovative approaches to operational excellence.

Let’s connect at !

A new article authored by Henrik Watz, MD, Principal Investigator at Velocity’s site in Ahrensburg, Germany, shows that ...
01/26/2026

A new article authored by Henrik Watz, MD, Principal Investigator at Velocity’s site in Ahrensburg, Germany, shows that body mass index (BMI) meaningfully influences COPD symptom scores independent of lung function.

In a large COPD cohort, overweight and obesity were consistently associated with a higher symptom burden and worse quality‑of‑life scores, even after adjustment for lung function, air trapping, gas transfer, exacerbation history, and relevant comorbidities. Symptom scores increased progressively from normal weight to overweight to obesity.

While effect sizes were modest, they were large enough to influence score‑based COPD categorization, suggesting that symptom‑based assessments may partly reflect body weight–related mechanical and systemic effects, not lung disease alone. These findings indicate that BMI should be considered when interpreting COPD symptom scores and risk stratification.

Read the full article: https://pmc.ncbi.nlm.nih.gov/articles/PMC12747889/

At  , Nick Spittal will join leaders from Advarra and Immunovant to share insights on how aligned workflows and connecte...
01/23/2026

At , Nick Spittal will join leaders from Advarra and Immunovant to share insights on how aligned workflows and connected technology can reduce inefficiencies and strengthen collaboration among Sponsors, CROs, and research sites.

Make sure to add the session to your calendar:
Meeting Sites Where They Are: Key Connections in Action
Wednesday, February 4, 2026 | 9:50am
Scope 2026 | Rosen Shingle Creek, Orlando

Address

300 E. Main Street , Suite 300
Durham, NC
27701

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+19199261804

Alerts

Be the first to know and let us send you an email when Velocity Clinical Research posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram